RECURRENT PERICARDITIS
TREATMENT
About the Disease
Recurrent pericarditis (RP) is a painful autoinflammatory cardiovascular disease that occurs when patients with acute pericarditis experience one or more pericarditis episodes after being symptom-free for 4-6 weeks. The symptoms associated with RP affect patients' quality of life, can limit physical activities, and lead to frequent emergency department visits and hospitalizations. RP can affect people of all ages and ethnicities, and it is estimated that 40,000 patients in the US seek treatment annually for RP.
About our Patient Care
Our dedicated Care Team works with the physician's office and insurance on a patient's behalf to give our patients more time to focus on their treatment. We are here to listen, provide counseling on treatment, including side-effect management, and assist with sourcing third-party financial assistance.
As part of our treatment and services, we provide:
Dedicated Care Team
We provide prescribers and patients with a dedicated care team for each of our disease-state programs. This includes a primary pharmacy contact, clinical education, side-effect management, scheduled refill calls, and a direct phone, fax, and email address.
Shipping and Coordination of Care
We provide free overnight delivery of medications and necessary medical supplies and manage care coordination between prescribers, sites of care, nurses, and patients to ensure dispense and drug delivery aligns with the date and location of service.
Financial Assistance
We identify and assist in enrolling patients into manufacturer financial assistance programs to minimize a potential financial burden to patients.
24/7/365 Access to a Pharmacist
We provide prescribers and patients access to a pharmacist 24/7/365 to ensure patients are always cared for.
Supported Treatments
Click on the specialty drug name below to expand and see more information.
ARCALYST® (rilonacept)
Brand Name | ARCALYST
Manufacturer | Kiniksa Pharmaceuticals (UK), Inc.
Route of Administration | Subcutaneous Injection
Approved Indication | ARCALYST is an interleukin-1 blocker indicated for:
-
Treatment of recurrent pericarditis (RP) and reduction in risk of recurrence in adults and pediatric patients 12 years and older
-
Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS) in adults and children 12 years and older
-
Maintenance of remission of Deficiency of Interleukin-1 Receptor Antagonist (DIRA) in adults and pediatric patients weighing 10 kg or more.
Self-Administration | Yes
Product Website | https://arcalyst.com
ARCALYST is a registered trademark of Regeneron Pharmaceuticals, Inc. and is exclusively licensed by Kiniksa Pharmaceuticals.